Skip to Main Content


Billingsley Named Chief Medical Officer at Smilow Cancer Hospital

September 20, 2019

After an extensive nationwide search, we are pleased to announce the appointment of Kevin G. Billingsley, M.D., as Chief Medical Officer at Smilow Cancer Hospital and Yale Cancer Center and Professor of Surgery at Yale School of Medicine. Billingsley starts in his new position January 2020.

“Dr. Billingsley’s experience and long record of accomplishments will be a great asset to Smilow Cancer Hospital and Yale Cancer Center as we continue to advance our vital mission of world renowned research and cancer care,” said Charles Fuchs, M.D., M.P.H., director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital.

As Chief Medical Officer, Billingsley will be responsible for clinical cancer care at Yale Cancer Center, Smilow Cancer Hospital and Smilow Cancer Hospital’s Network of 14 Care Centers throughout Connecticut, as well as clinical program development for cancer services throughout Yale New Haven Health. Among his many responsibilities, Billingsley will oversee quality and patient safety initiatives, evaluate and optimize our multidisciplinary team structure, assist with facilities/space planning, support our research mission, and interact and coordinate with Yale New Haven Hospital’s clinical leadership structure.

Billingsley trained in Surgical Oncology at Memorial Sloan Kettering Cancer Center, where he served as Administrative Chief Fellow. He graduated from Stanford University and received his medical degree from Johns Hopkins University School of Medicine. Billingsley is currently an MBA candidate at Oregon Health and Sciences University.

Billingsley joins Yale from Oregon Health and Sciences University (OHSU) where he currently serves as Medical Director of the OHSU Knight Cancer Institute, Chief of Surgical Oncology, and the Hedinger Professor of Surgical Oncology. He is an international leader in the clinical care and research of hepatobiliary cancers and serves as co-director of the Liver Tumor Program at OHSU.

Submitted by Anne Doerr on September 19, 2019